

MIGRAINE CALCITONIN GENE-RELATED PEPTIDE (CGRP) ANTAGONISTS ORAL

Nurtec ODT (rimegepant), Qulipta (atogepant), Ubrelvy* (ubrogepant)

*Prior authorization for this product applies only to formulary exceptions due to being a non-covered medication

Pre - PA Allowance

None

Prior-Approval Requirements**Nurtec ODT****Age** 18 years of age or older**Diagnoses**Patient must have **ONE** of the following:

1. Preventive treatment of episodic migraine **AND ALL** of the following:
 - a. Patient has **ONE** of the following:
 - i. Patient has taken a preventative CGRP medication in the past or is switching from another preventative CGRP medication
 - ii. Patient has had an inadequate treatment response, intolerance, or contraindication to at least **TWO** of the following prophylactic agents:
 - a) Divalproex sodium/valproate sodium (Depakote, Depakote ER)
 - b) Topiramate (Topamax)
 - c) Tricyclic antidepressants: amitriptyline (Elavil), nortriptyline (Pamelor)
 - d) Serotonin-norepinephrine reuptake inhibitors: venlafaxine (Effexor XR), duloxetine (Cymbalta)
 - e) Beta-blockers: atenolol, metoprolol, nadolol, propranolol, timolol
 - b. Patient has **ONE** of the following:
 - i. **NO** dual therapy with another CGRP antagonist (see Appendix 1)
 - ii. Dual therapy with a CGRP antagonist for acute treatment of migraine if **ONE** of the following applies:
 - a) Patient has completed an adequate 3-month trial of at least 2 preventative CGRP antagonists (i.e., Aimovig, Ajovy, Emgality, Nurtec ODT, Qulipta, and Vyepti)

MIGRAINE CALCITONIN GENE-RELATED PEPTIDE (CGRP) ANTAGONISTS ORAL

Nurtec ODT (rimegepant), Qulipta (atogepant), Ubrelvy* (ubrogepant)

*Prior authorization for this product applies only to formulary exceptions due to being a non-covered medication

- b) Patient has completed an adequate 3-month trial of a preventative CGRP antagonist in combination with a triptan agent
- 2. Acute treatment of migraine with or without aura **AND ALL** of the following:
 - a. Patient has completed an adequate 3-month trial **OR** patient has an intolerance or contraindication to at least **TWO** Triptan Agents
 - b. **NO** dual therapy with Triptan Agents at Prior Authorization quantities
 - c. Patient has **ONE** of the following:
 - i. **NO** dual therapy with another CGRP antagonist (see Appendix 1)
 - ii. Dual therapy with a migraine preventative CGRP antagonist if **ONE** of the following applies:
 - a) Patient has completed an adequate 3-month trial of at least 2 migraine preventative CGRP antagonists (i.e., Aimovig, Ajovy, Emgality, Nurtec ODT, Qulipta, and Vyepti)
 - b) Patient has completed an adequate 3-month trial of a migraine preventative CGRP antagonist in combination with a triptan agent

Qulipta**Age** 18 years of age or older**Diagnosis**

Patient must have the following:
Migraine

AND ALL of the following:

- a. Used for the prevention of migraines
- b. Patient has **ONE** of the following:
 - i. Patient has taken a preventative CGRP medication in the past or is switching from another preventative CGRP medication
 - ii. Patient has had an inadequate treatment response, intolerance, or contraindication to at least **TWO** of the following prophylactic agents:
 - a) Divalproex sodium/valproate sodium (Depakote, Depakote ER)

MIGRAINE CALCITONIN GENE-RELATED PEPTIDE (CGRP) ANTAGONISTS ORAL

Nurtec ODT (rimegepant), Qulipta (atogepant), Ubrelvy* (ubrogepant)

*Prior authorization for this product applies only to formulary exceptions due to being a non-covered medication

- b) Topiramate (Topamax)
- c) Tricyclic antidepressants: amitriptyline (Elavil), nortriptyline (Pamelor)
- d) Serotonin-norepinephrine reuptake inhibitors: venlafaxine (Effexor XR), duloxetine (Cymbalta)
- e) Beta-blockers: atenolol, metoprolol, nadolol, propranolol, timolol
- c. Patient has **ONE** of the following:
 - i. **NO** dual therapy with another CGRP antagonist (see Appendix 1)
 - ii. Dual therapy with a CGRP antagonist for acute treatment of migraine if **ONE** of the following applies:
 - a) Patient has completed an adequate 3-month trial of at least 2 migraine preventative CGRP antagonists (i.e., Aimovig, Ajovy, Emgality, Nurtec ODT, Qulipta, and Vyepti)
 - b) Patient has completed an adequate 3-month trial of a migraine preventative CGRP antagonist in combination with a triptan agent

Ubrelvy Prior authorization for Ubrelvy applies only to formulary exceptions due to being a non-covered medication

Age 18 years of age or older

Diagnosis

Patient must have the following:

1. Acute treatment of migraine with or without aura **AND ALL** of the following:
 - a. **NOT** used for the prevention of migraines
 - b. Patient has completed an adequate 3-month trial **OR** patient has an intolerance or contraindication to at least **TWO** Triptan Agents
 - c. **NO** dual therapy with Triptan Agents at Prior Authorization quantities
 - d. Patient has **ONE** of the following:
 - i. **NO** dual therapy with another CGRP antagonist (see Appendix 1)
 - ii. Dual therapy with a migraine preventative CGRP antagonist if **ONE** of the following applies:
 - a) Patient has completed an adequate 3-month trial of at least 2 migraine preventative CGRP antagonists (i.e., Aimovig, Ajovy, Emgality, Nurtec ODT, Qulipta, and Vyepti)

MIGRAINE CALCITONIN GENE-RELATED PEPTIDE (CGRP) ANTAGONISTS ORAL

Nurtec ODT (rimegepant), Qulipta (atogepant), Ubrelvy* (ubrogepant)

*Prior authorization for this product applies only to formulary exceptions due to being a non-covered medication

- b) Patient has completed an adequate 3-month trial **of** a migraine preventative CGRP antagonist in combination with a triptan agent

Prior-Approval Limits

Quantity

Medication/Strength	Diagnosis	Quantity
Nurtec ODT 75 mg	Preventative treatment	48 tablets per 90 days OR
Nurtec ODT 75 mg	Acute treatment	56 tablets per 90 days OR
Qulipta 10 mg, 30 mg, 60 mg	Preventative treatment	90 tablets per 90 days OR

Medication/Strength <u>with Approved Formulary Exception (FE) Only</u>	Diagnosis	Quantity
Ubrelvy 50 mg tablets	Acute treatment	96 tablets per 90 days OR
Ubrelvy 100 mg tablets	Acute treatment	48 tablets per 90 days

Duration 6 months

Prior – Approval *Renewal* Requirements

Nurtec ODT

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Preventive treatment of episodic migraine **AND ALL** of the following:
 - a. Documented decrease in migraine days from baseline **OR** improvement in daily activities due to the reduction of debilitating migraine
 - b. Patient has **ONE** of the following:
 - i. **NO** dual therapy with another CGRP antagonist (see Appendix 1)
 - ii. Dual therapy with a CGRP antagonist for acute treatment of migraine if **ONE** of the following applies:

MIGRAINE CALCITONIN GENE-RELATED PEPTIDE (CGRP) ANTAGONISTS ORAL

Nurtec ODT (rimegepant), Qulipta (atogepant), Ubrelvy* (ubrogepant)

*Prior authorization for this product applies only to formulary exceptions due to being a non-covered medication

- a) Patient has completed an adequate 3-month trial of at least 2 preventative CGRP antagonists (i.e., Aimovig, Ajovy, Emgality, Nurtec ODT, Qulipta, and Vyepti)
 - b) Patient has completed an adequate 3-month trial of a preventative CGRP antagonist in combination with a triptan agent
2. Acute treatment of migraine with or without aura **AND ALL** of the following:
- a. **NO** dual therapy with Triptan Agents at Prior Authorization quantities
 - b. Patient has **ONE** of the following:
 - i. **NO** dual therapy with another CGRP antagonist (see Appendix 1)
 - ii. Dual therapy with a migraine preventative CGRP antagonist if **ONE** of the following applies:
 - a) Patient has completed an adequate 3-month trial of at least 2 migraine preventative CGRP antagonists (i.e., Aimovig, Ajovy, Emgality, Nurtec ODT, Qulipta, and Vyepti)
 - b) Patient has completed an adequate 3-month trial of a migraine preventative CGRP antagonist in combination with a triptan agent

Qulipta

Age 18 years of age or older

Diagnosis

Patient must have the following:

Migraine

AND ALL of the following:

- 1. Used for the prevention of migraine
- 2. Documented decrease in migraine days from baseline **OR** improvement in daily activities due to the reduction of debilitating migraine
- 3. Patient has **ONE** of the following:
 - a. **NO** dual therapy with another CGRP antagonist (see Appendix 1)
 - b. Dual therapy with a CGRP antagonist for acute treatment of migraine if **ONE** of the following applies:

MIGRAINE CALCITONIN GENE-RELATED PEPTIDE (CGRP) ANTAGONISTS ORAL

Nurtec ODT (rimegepant), Qulipta (atogepant), Ubrelvy* (ubrogepant)

*Prior authorization for this product applies only to formulary exceptions due to being a non-covered medication

- i. Patient has completed an adequate 3-month trial of at least 2 migraine preventative CGRP antagonists (i.e., Aimovig, Ajovy, Emgality, Nurtec ODT, Qulipta, and Vyepti)
- ii. Patient has completed an adequate 3-month trial of a migraine preventative CGRP antagonist in combination with a triptan agent

Ubrelvy *Prior authorization for Ubrelvy applies only to formulary exceptions due to being a non-covered medication*

Age 18 years of age or older

Diagnosis

Patient must have the following:

1. Acute treatment of migraine with or without aura **AND ALL** of the following:
 - a. **NOT** used for the prevention of migraines
 - b. **NO** dual therapy with Triptan Agents at Prior Authorization quantities
 - c. Patient has **ONE** of the following:
 - i. **NO** dual therapy with another CGRP antagonist (see Appendix 1)
 - ii. Dual therapy with a migraine preventative CGRP antagonist if **ONE** of the following applies:
 - a) Patient has completed an adequate 3-month trial of at least 2 migraine preventative CGRP antagonists (i.e., Aimovig, Ajovy, Emgality, Nurtec ODT, Qulipta, and Vyepti)
 - b) Patient has completed an adequate 3-month trial of a migraine preventative CGRP antagonist in combination with a triptan agent

Prior - Approval *Renewal* Limits

Quantity

Medication/Strength	Diagnosis	Quantity
Nurtec ODT 75 mg	Preventative	48 tablets per 90 days OR

MIGRAINE CALCITONIN GENE-RELATED PEPTIDE (CGRP) ANTAGONISTS ORAL

Nurtec ODT (rimegepant), Qulipta (atogepant), Ubrelvy* (ubrogepant)

*Prior authorization for this product applies only to formulary exceptions due to being a non-covered medication

	treatment	
Nurtec ODT 75 mg	Acute treatment	56 tablets per 90 days OR
Qulipta 10 mg, 30 mg, 60 mg	Preventative treatment	90 tablets per 90 days OR

Medication/Strength <u>with</u> <u>Approved Formulary</u> <u>Exception (FE) Only</u>	Diagnosis	Quantity
Ubrelvy 50 mg tablets	Acute treatment	96 tablets per 90 days OR
Ubrelvy 100 mg tablets	Acute treatment	48 tablets per 90 days

Duration 12 months

Appendix 1 - List of CGRP Antagonists

Generic Name	Brand Name
atogepant	Qulipta
eptinezumab-jjmr	Vyepti
erenumab-aooe	Aimovig
fremanezumab-vfrm	Ajovy
galcanezumab-gnim	Emgality
rimegepant	Nurtec ODT
ubrogepant	Ubrelvy
zavegepant	Zavzpret